AWMSG advice
Raltegravir (Isentress®) 100 mg granules for oral suspension, in combination with other anti-retroviral medicinal products for the treatment of human immunodeficiency virus (HIV-1) infection in adults, adolescents, children, toddlers and infants from the age of four weeks are recommended as an option for restricted use within NHS Wales.
Raltegravir (Isentress®) 100 mg granules for oral suspension should be restricted for use in patients who are resistant or intolerant to non-nucleoside reverse transcriptase inhibitors (NNRTIs) or protease inhibitors (PIs), or for whom these options are compromised due to drug–drug interactions.
